Panaxia Labs Israel Ltd. reported financial results for the second quarter and first half of 2020. The company's revenues in the second quarter of 2020 totaled a record of ILS 14.8 million, an increase of 374%, more than four times revenues of ILS 3.1 million in the same period of last year, and a 21%-increase over 12.2 million in the first quarter of 2020. The gross profit in the second quarter of 2020, under the new regulation, totaled ILS 1.2 million, an increase of 195% compared with gross profit of ILS 413,000 in the previous quarter, and gross loss, under the previous regulation of 389 thousand in the same quarter of last year. The company's revenues in the first half of 2020 totaled ILS 26.9 million, an increase of 370% or over four times the revenues of ILS 5.7 million in the same period of last year, and 145% over 11 million in the second half of 2019. The gross profit in the first half of 2020 totaled ILS 1.6 million, compared with a gross loss of ILS 102 thousand in the same quarter of last year, under the previous regulation, and a gross loss of ILS 1.8 million in the second half of 2019.